ABVC BioPharma, Inc. Achieves Significant Asset Growth and Licensing Revenue in Q2 2025

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company, has announced its financial results for the second quarter of 2025, showcasing a remarkable 103% year-over-year growth in total consolidated assets, now standing at $16.2 million. This growth is attributed to stronger affiliate equity positioning and improved asset allocation, marking a significant milestone in the company's strategic consolidation efforts.

The company also reported an increase in shareholders' equity to $9.5 million from $8.0 million in the same period last year, reflecting a disciplined approach to capital structure and operational streamlining. Furthermore, ABVC's diluted loss per share showed a notable improvement, decreasing to $(0.13) in Q2 2025 from $(0.42) in 2024, underscoring the effectiveness of its cost-reduction and high-value growth initiatives.

In a strategic move to bolster its research and development capabilities, ABVC completed the acquisition of farmland in Taiwan valued at approximately $3.3 million. This acquisition is expected to support the company's expansion in Asia by facilitating botanical ingredient cultivation and the development of modular R&D facilities, thereby enhancing vertical integration and reducing dependency on external suppliers.

Adding to its Q2 achievements, ABVC secured $350,000 in licensing revenue in July 2025 from three partners, including AiBtl BioPharma, Inc., OncoX BioPharma, Inc., and ForSeeCon Eye Corporation. This revenue, to be recognized in Q3 2025, exemplifies the company's successful execution of its monetization strategy and its ability to generate non-dilutive revenue streams.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the company's strategic discipline and its commitment to sustainable long-term growth and shareholder value creation. With a pipeline of six drugs and one medical device under development, ABVC continues to leverage its network of renowned research institutions to advance its clinical-stage biopharmaceutical solutions.

For more detailed information about ABVC BioPharma and its financial performance, investors are encouraged to review the company's filings with the Securities and Exchange Commission (SEC) available at http://www.sec.gov.